174 related articles for article (PubMed ID: 31091104)
21. Sympathetic nerve repulsion inhibited by designer molecules in vitro and role in experimental arthritis.
Kunath J; Delaroque N; Szardenings M; Neundorf I; Straub RH
Life Sci; 2017 Jan; 168():47-53. PubMed ID: 27856318
[TBL] [Abstract][Full Text] [Related]
22. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Li J; Ny A; Leonardsson G; Nandakumar KS; Holmdahl R; Ny T
Am J Pathol; 2005 Mar; 166(3):783-92. PubMed ID: 15743790
[TBL] [Abstract][Full Text] [Related]
23. Total abrogation of collagen II-induced arthritis and the B cell response to type II collagen using suboptimal doses of a topoisomerase II antagonist.
Verdrengh M; Jonsson IM; Zaether O; Bajtner E; Holmdahl R; Tarkowski A
Ann Rheum Dis; 2002 Sep; 61(9):829-31. PubMed ID: 12176810
[TBL] [Abstract][Full Text] [Related]
24. Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody.
Topping LM; Thomas BL; Rhys HI; Tremoleda JL; Foster M; Seed M; Voisin MB; Vinci C; Law HL; Perretti M; Norling LV; Azevedo HS; Nissim A
Front Immunol; 2020; 11():10. PubMed ID: 32117219
[TBL] [Abstract][Full Text] [Related]
25. Amelioration of collagen antibody induced arthritis in mice by an antibody directed against the fibronectin type III repeats of tenascin-C: Targeting fibronectin type III repeats of tenascin-C in rheumatoid arthritis.
Mehta BB; Tiwari A; Sharma S; Shukla A; Sharma M; Vasishta RK; Sen RK; Sharma A; Luthra-Guptasarma M
Int Immunopharmacol; 2018 May; 58():15-23. PubMed ID: 29529488
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis.
Verdrengh M; Isaksson O; Tarkowski A
Rheumatology (Oxford); 2005 Feb; 44(2):183-6. PubMed ID: 15494349
[TBL] [Abstract][Full Text] [Related]
27. Collagen autoimmune arthritis.
Stuart JM; Townes AS; Kang AH
Annu Rev Immunol; 1984; 2():199-218. PubMed ID: 6399847
[TBL] [Abstract][Full Text] [Related]
28. Torilin ameliorates type II collagen-induced arthritis in mouse model of rheumatoid arthritis.
Endale M; Lee WM; Kwak YS; Kim NM; Kim BK; Kim SH; Cho J; Kim S; Park SC; Yun BS; Ko D; Rhee M
Int Immunopharmacol; 2013 Jun; 16(2):232-42. PubMed ID: 23623942
[TBL] [Abstract][Full Text] [Related]
29. Complement deficiency ameliorates collagen-induced arthritis in mice.
Hietala MA; Jonsson IM; Tarkowski A; Kleinau S; Pekna M
J Immunol; 2002 Jul; 169(1):454-9. PubMed ID: 12077276
[TBL] [Abstract][Full Text] [Related]
30. [Animal models for bone and joint disease. CIA, CAIA model].
Hirose J; Tanaka S
Clin Calcium; 2011 Feb; 21(2):253-9. PubMed ID: 21289422
[TBL] [Abstract][Full Text] [Related]
31. Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis.
Jin CH; Chae SY; Kim TH; Yang HK; Lee EY; Song YW; Jo DG; Lee KC
J Pharmacol Exp Ther; 2010 Mar; 332(3):858-65. PubMed ID: 19933369
[TBL] [Abstract][Full Text] [Related]
32. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis.
Put S; Schoonooghe S; Devoogdt N; Schurgers E; Avau A; Mitera T; D'Huyvetter M; De Baetselier P; Raes G; Lahoutte T; Matthys P
J Nucl Med; 2013 May; 54(5):807-14. PubMed ID: 23447654
[TBL] [Abstract][Full Text] [Related]
33. Factors secreted from dental pulp stem cells show multifaceted benefits for treating experimental rheumatoid arthritis.
Ishikawa J; Takahashi N; Matsumoto T; Yoshioka Y; Yamamoto N; Nishikawa M; Hibi H; Ishigro N; Ueda M; Furukawa K; Yamamoto A
Bone; 2016 Feb; 83():210-219. PubMed ID: 26603475
[TBL] [Abstract][Full Text] [Related]
34. Chemical changes demonstrated in cartilage by synchrotron infrared microspectroscopy in an antibody-induced murine model of rheumatoid arthritis.
Croxford AM; Nandakumar KS; Holmdahl R; Tobin MJ; McNaughton D; Rowley MJ
J Biomed Opt; 2011 Jun; 16(6):066004. PubMed ID: 21721805
[TBL] [Abstract][Full Text] [Related]
35. YKL-39, a human cartilage-related protein, induces arthritis in mice.
Sakata M; Masuko-Hongo K; Tsuruha J; Sekine T; Nakamura H; Takigawa M; Nishioka K; Kato T
Clin Exp Rheumatol; 2002; 20(3):343-50. PubMed ID: 12102470
[TBL] [Abstract][Full Text] [Related]
36. Kinsenoside inhibits the inflammatory mediator release in a type-II collagen induced arthritis mouse model by regulating the T cells responses.
Hsiao HB; Hsieh CC; Wu JB; Lin H; Lin WC
BMC Complement Altern Med; 2016 Feb; 16():80. PubMed ID: 26916550
[TBL] [Abstract][Full Text] [Related]
37. Passive transfer of collagen arthritis: studies with affinity-purified anticollagen IgG prepared in rabbits.
Ridge SC; McReynolds RA; Mitcho YL; Bauman N; Oronsky AL; Kerwar SS
Clin Immunol Immunopathol; 1984 Dec; 33(3):402-11. PubMed ID: 6388928
[TBL] [Abstract][Full Text] [Related]
38. Complement receptor CR2/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens.
Kuhn KA; Cozine CL; Tomooka B; Robinson WH; Holers VM
Mol Immunol; 2008 May; 45(10):2808-19. PubMed ID: 18374982
[TBL] [Abstract][Full Text] [Related]
39. Water-soluble undenatured type II collagen ameliorates collagen-induced arthritis in mice.
Yoshinari O; Shiojima Y; Moriyama H; Shinozaki J; Nakane T; Masuda K; Bagchi M
J Med Food; 2013 Nov; 16(11):1039-45. PubMed ID: 24175655
[TBL] [Abstract][Full Text] [Related]
40. Genetic control of antibody production during collagen-induced arthritis development in heterogeneous stock mice.
Förster M; Raposo B; Ekman D; Klaczkowska D; Popovic M; Nandakumar KS; Lindvall T; Hultqvist M; Teneva I; Johannesson M; Ahlqvist E; Holmdahl R
Arthritis Rheum; 2012 Nov; 64(11):3594-603. PubMed ID: 22886420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
